11:02 am ZIOPHARM presents preclinical data at AACR Annual Meeting supporting controlled DNA-based IL-12 therapy for brain cancer; data demonstrated that administration of Ad-RTS-mIL-12 + veledimex resulted in dose-related increases in surv